Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Mitsubishi Chemical Holdings to Invest in New Production Facilities for Drugs and Vaccines
December 10, 2015
- Stephen Hitchcock Tapped as Head of Pharma Research at Takeda
December 9, 2015
- Takeda Ties Up with US Biotech Cour on Immune Modulating Therapies
December 9, 2015
- Ethical Drug Sales Zoom 10.7% in October: Crecon Report
December 9, 2015
- Mega Mergers Not the Best Way to Get Drug Discovery Prowess: Astellas President
December 9, 2015
- Sovaldi Top-Prescribed Drug at Japanese Acute Hospitals in July-Sept.
December 8, 2015
- Belsomra Most Promoted Drug for GPs for 4 Months Running: Anterio
December 8, 2015
- Otsuka Seeks Japan Approval of Abilify for Juvenile Autism-Linked Excitability
December 8, 2015
- MM Treatment Ixazomib Extends PFS in PIII: Takeda
December 8, 2015
- Nothing Decided for Japan Market over Pfizer’s Allergan Acquisition: Umeda
December 7, 2015
- Global PII for Pediatric X-Linked Hypophosphatemia Yields Positive Data: Kyowa Kirin
December 7, 2015
- Kyowa Kirin Kicks Off Global PIII for Adult X-Linked Hypophosphatemia
December 7, 2015
- Unusualness of Hep C Market Not Being Understood, Gilead COO Says on Possible Sovaldi Re-Pricing
December 4, 2015
- Nichi-Iko Sells Off Shares Held in South Korean Firm
December 3, 2015
- GSK’s Drug Supplies Disrupted by Manufacturing Woes Overseas
December 2, 2015
- Japan NDA for IBS-C Drug Linaclotide Planned in 2016: Astellas
December 2, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Daiichi Sankyo to Shutter German Biotech Unit amid R&D Cost-Cut Drive
December 2, 2015
- Kyowa Kirin Launches Japan PIII Study for Regpara Successor
December 2, 2015
- Ole Moelskov Bech to Lead Novo Nordisk Japan from January
December 2, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…